3 completed, 1 withdrawn. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
Follow xenin 25: new trials by email Literature Review of xenin 25 trials Research Report on xenin 25
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion Control, Xenin-25 without atropine, GIP without atropine - Pre-diabetes | Phase 1 | Completed | Washington University School of Medicine | 15 | 2013-03-13 | 2018-05-25 |
| Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone - Does the Vagus Nerve Mediate the Effects of Xenin-25 | Phase 1 | Withdrawn | Washington University School of Medicine | 2013-01-01 | 2018-04-26 | |
| Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Washington University School of Medicine | 38 | 2009-10-01 | 2014-07-22 |
| Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Diabetes | Phase 1 | Completed | Washington University School of Medicine | 40 | 2008-12-01 | 2018-05-03 |
Insulin Resistance (3) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (1) · Glucose Intolerance (1)
Washington University School of Medicine (4)
United States (4)
Dominic Reeds, MD (4) · Burton M Wice, PhD (2) · Burton Wice, PhD (2)
PMID 22522617, PMID 24183983, PMID 24356886
1RC1DK086163-01 (1), R01DK088126 (1)